Equity
€355,552 ▲ 10.4%
MEDIBAK paid out €320,460 in dividends. That is 91% of the 2025 profit.
MEDIBAK
Lifetime
6 annual accounts with figures on one time axispeak €480,427 (2025)
€480,427▲ 9.5%
peak €354,052 (2025)
€354,052▲ 10.5%
peak €649,797 (2022)
€355,552▲ 10.4%
€361,281▲ 137%
Board1 name since 2019
1 director
Documentsfilings and deeds
14-07-202617 days before the deadline
2025micro format
Dividend €320,460Debts from €152,304 to €361,281Cash from €13,956 to €37,889
Key points
from the 2025 annual accountsTurnover
≈ €720,000 estimated
The micro format states no turnover.
Debts
€361,281 ▲ 137%
Debts rose by €208,977 in 2025.
Liquidity
4.78 was 3.11 in 2024
Short-term debts fell from €152,304 to €149,888.
Filings
6 annual accounts since 2020
The last five annual accounts were filed 1 to 45 days before the end of the period.
Position in the sector
€354,052
Higher net result than 95% of companies in human health. Sector median €59,563 · 21,309 companies.
Checked score
Bankruptcy probability within 12 months
Financial strength
Score breakdown
Comparable companies, two years later
In July 2024, 6,783 companies had the same profile as MEDIBAK has now. Each dot stands for 17 companies, two years later.
96.7%
were still trading
2.7%
stopped another way
0.6%
went bankrupt
Test of the method
The method was tested on the 497,762 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 2.9% | 3.1% |
| 10 | 5.6% | 6.1% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 6,783 companies, not a prediction for MEDIBAK. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Credit verdict
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Recent changes
Registered in the Peppol Directory
Reachable for e-invoices through 9925:BE0738676972
Incorporation
Founding capital of €1,500, 100 shares · Founder: (comparant) · Appointment: (director) · published on 05-12-2019 · Gazette deed
First establishment
Melkerijstraat 136, Molenbeek-Saint-Jean
Comparable companies
same main activity, similar in size and age| Company | ||||
|---|---|---|---|---|
| MEDIBAK Molenbeek-Saint-Jean | €716,833 | €480,427 | 49.6% | - |
| DR. WANNES BAETEN, ANESTHESIE Ghent | €702,865 | €482,389 | 90.7% | - |
| Dr. VAN WAMBEKE SIMON Kapellen | €700,448 | €471,309 | 47.4% | - |
| DR. TOM VAN DEN MOOTER Mechelen | €722,004 | €512,454 | 52.5% | - |
| Dr. Hannelore Bode Roeselare | €735,607 | €513,010 | 30.0% | - |
| DR. YANNICK MANDEVILLE Zedelgem | €638,144 | €497,053 | 11.1% | - |
| CABINET OPHTALMOLOGIQUE LES MEDECINS ASSOCIES Olne | €625,762 | €487,835 | 0.8% | 3 |
These companies have the same main activity as MEDIBAK: specialist medical practice (NACE 86220). They are comparable in size and age: total assets between €626,000 and €736,000, founded between 2019 and 2020.
Official details
Source: KBO- Status
- Active since 03-12-2019Normal situation
- Activity
- Specialist medical practiceNACE 86220
- Establishment unit
- 2.297.321.2741080 Molenbeek-Saint-Jean, since 03-12-2019
- Financial year end
- 31 December
- Peppol
- Reachable since 19-12-2025
Annual accounts 2025
- €716,833▲ 51.1%
- Filing
- Filed on 14-07-2026, 17 days before the end of the filing period
Insights on MEDIBAK
MEDIBAK files the micro format. That format states no turnover. The gross margin rose from €236,610 in 2020 to €480,427 in 2025.
Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.
Key facts about MEDIBAK
- What is the company number of MEDIBAK?
- The company number of MEDIBAK is 0738.676.972. The VAT number is the same number with BE in front: BE 0738.676.972.
- Where is MEDIBAK based?
- The registered office is at Melkerijstraat 136, 1080 Molenbeek-Saint-Jean.Company details
- What does MEDIBAK do?
- According to the KBO register, the main activity is specialist medical practice (NACE 86220).
- What is the legal form of MEDIBAK?
- MEDIBAK is a private limited company (BV).
- When was MEDIBAK founded?
- MEDIBAK was founded on 03-12-2019.
- Is MEDIBAK still active?
- Yes, MEDIBAK is an active enterprise in the KBO register.
- What is the turnover of MEDIBAK?
- The turnover in financial year 2025 is ≈ €720,000. This figure is estimated from the gross margin of €480,427 and 31 comparable companies (NACE 86220). It probably lies between €640,000 and €1.0m.Financials
- Is MEDIBAK profitable?
- In financial year 2025, MEDIBAK made a profit of €354,052.
- Where can I find the annual accounts of MEDIBAK?
- MEDIBAK filed 6 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of MEDIBAK due?
- MEDIBAK must file the annual accounts for financial year 2026 by 31-07-2027.Timeline
Next steps
Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Check which of your other customers you can e-invoice via Peppol.Peppol check Compare this company with its sector.Sector benchmark See what changed in the latest annual accounts.What changed
See how customers, suppliers and banks see your own company and what to improve first.